Germany Added 2.5 Million Women to Mammography Screening While Reopening Skin Cancer Screening After a Proposal to Suspend It
Germany is widening cancer screening where the evidence is settled and reopening it where cost is the question.
Market Access
One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price
One price in Japan, response-linked payments in Australia, no public price in China: CAR-T sponsors face three markets.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response
Denmark turned a January no on Tecartus into a yes by tying price to response, and renewed burosumab on a lower price.
Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS
Exclusion only works as leverage when the excluded drug has no market. Mounjaro has one, and Lilly built the channel.
ICER Says AstraZeneca’s $10,950 Baxfendy Is Worth $1,400 to $2,500 a Year
ICER has handed payers the case for putting Baxfendy behind generics, and Mineralys gets its price anchor before launch.
Latvia Squeezes Access for 123,000 Patients Out of Price Deals as 124 Drugs Wait
Latvia is buying access with manufacturers’ money, inside a reimbursement budget NVD already expects to overrun.
NICE Backs Tryngolza for FCS, Giving Sobi a Monthly Successor to Its Own Waylivra
Sobi is moving its FCS franchise to a less frequent, better-tolerated drug, on broader NICE terms than the one it replaces.
Pharmac Will Fund Any Medicine for Young People With Paediatric-Origin Cancers, About 15 a Year
The numbers are small, but the rule is unusual: New Zealand funds by tumour type and protocol rather than product by product.
Korea Now Reimburses BeOne’s Tevimbra First-Line in Three Cancers, Using PD-L1 Cutoffs to Set the Limits
One reimbursement decision moved a second-line PD-1 into first line across three common cancers, inside biomarker limits.